Year: 2017
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Introduction Multiple intravenous doses of ponezumab, an anti‐amyloid antibody, were evaluated in subjects with mild‐to‐moderate Alzheimer's disease (AD). Methods In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 63 subjects were randomized and treated with ponezumab 3 or 8.5 mg/kg and 32 with placebo. Subjects received 10 infusions over 18 months and were followed for 6 months thereafter. Results Ponezumab was generally safe and well tolerated. Most common adverse events were fall (16.7% ponezumab, 21.4% placebo), headache (13.8%, 21.4%), and cerebral microhemorrhage (13.8%, 19.6%). Plasma ponezumab increased dose‐dependently with limited accumulation. Cerebrospinal fluid penetration was low. Plasma Aβ 1–x and Aβ 1–40 showed robust increases, but cerebrospinal fluid biomarkers showed no dose response. Ponezumab had no effects on cognitive/functional outcomes or brain volume. Conclusions Multiple‐dose ponezumab was generally safe, but not efficacious, in mild‐to‐moderate AD.
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,540
Awards: Sex-specific Risk for Vascular Dysfunction and Cognitive Decline, Pathological basis of MRS and DTI changes in neurodegenerative dementia, Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers, Alzheimer's Disease Neuroimaging Initiative, G5884129571, Stroke and Cognitive Impairment in Aging Chronic Kidney Disease Patients, Dominantly Inherited Alzheimer Network, Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W2613104019
